This archived content created prior to April 24, 2026 is being made available for reference, research, or recordkeeping purposes only and may not meet current web content accessibility standards. If required, an accessible version of this content can be made on request.
The National Cancer Institute has awarded University of Hawaiʻi Cancer Center's Alexandra Binder, ScD, $1.8 million to investigate how epigenetic age can be used to characterize the risk of chemotherapy side effects, and whether an exercise intervention can reduce the rate of epigenetic aging over treatment. Binder and collaborators hope to use findings from this study to improve health outcomes and quality of life for colon cancer patients who receive chemotherapy treatment.
Chemotherapy, a common form of cancer treatment, uses powerful drugs to kill cancer cells. These drugs can also damage non-cancer cells, contributing to adverse side effects. "Patients receiving chemotherapy may experience fatigue, hair loss, easy bruising and bleeding, infection, anemia, nausea, appetite changes, and nerve problems," said Binder. "Our goal is to appraise whether measuring a patient's epigenetic age can inform more personalized treatment plans that minimize the acute and long-term health burdens of chemotherapy-associated toxicities."
Epigenetic age measures whether an individual is aging faster than others of the same age based on specific patterns of gene regulation. These patterns of gene regulation can change with time and are shaped by the environment and behaviors of an individual across their lifespan. There is strong evidence that epigenetic age can be used to predict risk for cancer, heart disease, other illnesses, and overall mortality.
Through this project, Binder and her colleagues will determine whether epigenetic age can be used to identify colon cancer patients at high risk for chemotherapy-associated toxicities. They will further examine whether a resistance training intervention can reduce the rate of epigenetic aging during chemotherapy treatment. Findings from these investigations may help doctors to better tailor a patient's treatment regimen and exercise guidelines to lessen the harmful effects of cancer treatment.
###
About the University of Hawaiʻi Cancer Center
The University of Hawaiʻi Cancer Center is dedicated to saving lives in Hawaiʻi and the Pacific, and inspiring hope by working to conquer cancer. The flagship priority is to understand and address cancer health disparities. The center strives to achieve this through research, education, patient care, and community outreach, focusing on the unique and diverse ethnic, cultural, and environmental characteristics of Hawaiʻi and the Pacific.
The UH Cancer Center is one of only 74 institutions designated by the National Cancer Institute (NCI), representing a significant mark of excellence, and is the only NCI-designated cancer center in Hawaiʻi and the Pacific. The center contributes more than $57 million to Hawaiʻi's economy through scientific research, clinical trials, and other activities.
As part of the University of Hawaiʻi at Mānoa, the UH Cancer Center operates out of facilities located in Kakaʻako. The center directly employs more than 300 faculty and staff, with an additional 200 affiliate members and cooperative agreements with organizations that are part of the Hawaiʻi Cancer Consortium. The consortium includes The Queen’s Health Systems, Hawaiʻi Pacific Health, Kuakini Medical Center, Adventist Health Castle, Hawaiʻi Medical Service Association (HMSA), and the John A. Burns School of Medicine (JABSOM), all working together with the UH Cancer Center to advance cancer research and treatment in the state.
Learn more at https://www.uhcancercenter.org | Connect with us on Facebook | Instagram | X | LinkedIn